References
- Nilausen DØ ZuikerRvan GervenJThe perception and pharmacokinetics of a 20-mg dose of escitalopram orodispersible tablets in a relative bioavailability study in healthy menClin Ther201133101492150221999886
- HunterPCCrameriJAustinSWoodwardMCHughesAJResponse of parkinsonian swallowing dysfunction to dopaminergic stimulationJ Neurol Neurosurg Psychiatry19976355795839408096
- NavarroVImproving medication compliance in patients with depression: Use of orodispersible tabletsAdv Ther2010271178579520878372
- LlorcaPMDiscussion of prevalence and management of discomfort when swallowing pills: orodispersible tablets expand treatment options in patients with depressionTher Deliv20112561162222833978
- AndersenOZweidorffOKHjeldeTRødlandEAProblems when swallowing tablets. A questionnaire study from general practiceTidsskr Nor Laegeforen19951158947949 Norwegian7709385
- Márquez-ContrerasEGilVLópezJPharmacological compliance and acceptability of lansoprazole orally disintegrating tablets in primary careCurr Med Res Opin200824256957618194594
- KohNSakamotoSChinoFImprovement in medication compliance and glycemic control with voglibose oral disintegrating tabletTohoku J Exp Med2008216324925718987459
- ZigmondASSnaithRPThe hospital anxiety and depression scaleActa Psychiatr Scand1983673613706880820
- WadeAGCrawfordGMBezlyakVWellbeing of patients prescribed long-term SSRIs by general practitioners in the UK [abstract]Eur Neuropsychopharmacol200818Suppl 4S333
- ReganJSowmanRWalshIPrevalence of dysphagia in acute and community mental health settingsDysphagia20062129510116763936
- RooseSPCompliance: the impact of adverse events and tolerability on the physician’s treatment decisionsEur Neuropsychopharmacol200313Suppl 3S859214550581
- BenkertOSzegediAPhilippMMirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorderJ Clin Psychopharmacol200626757816415711